BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
David Lavie(Hadassah Medical Center), Rosa Ayala(Hospital Universitario 12 De Octubre), Oriana Esposito, Moshe Talpaz(University of Michigan), Michaël Loschi(Hôpital l'Archet), Jean‐Christophe Ianotto(Inserm), Maan Alwan, Indu Raman(Epworth Hospital), Jesús María Hernández‐Rivas(Universidad de Salamanca), Valentín García‐Gutiérrez(Universidad de Alcalá), Shodeinde Coker(Bristol-Myers Squibb (United States)), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Adi Abulafia, Haifa Kathrin Al‐Ali(University Hospital in Halle), Vincent Ribrag(Institut Gustave Roussy), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Costas K. Yannakou(Epworth Hospital), Massimiliano Bonifacio(University of Verona), Christopher Tehlirian(Bristol-Myers Squibb (United States)), Sharmila Das(Bristol-Myers Squibb (United States)), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Zariana Nikolova(Bristol-Myers Squibb (Switzerland)), Ciprian Tomuleasa(Iuliu Hațieganu University of Medicine and Pharmacy), Jonathan M. Gerber(UMass Memorial Health Care), Si Tuen Lee-Hoeflich(Bristol-Myers Squibb (United States)), Eunhee Kim(Smith Family), Yu Liu(Peking University), Qian Zhao(Baotou Medical College), Jean‐Jacques Kiladjian(Délégation Paris 5), Bin Wu(Jiangsu Provincial Center for Disease Control and Prevention), Yulia Volchek(Assaf Harofeh Medical Center)
Cited by 7
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k